Aflibercept reduces rate of diabetic disease progression in Protocol W


We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].

In this Healio Video Perspective from the virtual ARVO meeting, Jennifer Lim, MD, discusses results from the ongoing Protocol W study of aflibercept in eyes with nonproliferative diabetic retinopathy.

At the end of 2 years, Protocol W did not show a difference in visual acuity between the two groups of eyes in the study but did show a reduction in the rates of progression from moderate and severe nonproliferative diabetic retinopathy to proliferative diabetic retinopathy and center-involved diabetic macular edema. There was also less need for aflibercept-treated eyes to require rescue treatment for PDR or center-involved DME.


Source link

Kathy Laura

Leave a Reply

Your email address will not be published. Required fields are marked *